vs
Day One Biopharmaceuticals, Inc.（DAWN）与i3 Verticals, Inc.（IIIV）财务数据对比。点击上方公司名可切换其他公司
i3 Verticals, Inc.的季度营收约是Day One Biopharmaceuticals, Inc.的1.3倍（$52.7M vs $39.8M），i3 Verticals, Inc.净利率更高（0.9% vs -49.6%，领先50.5%），i3 Verticals, Inc.同比增速更快（-14.6% vs -57.6%）
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
Prusa i3是捷克Prusa Research公司生产的熔融沉积成型3D打印机系列，以Original Prusa i3为注册商标推出，同时也是RepRap项目的组成部分。2016年该系列就被评为全球使用率最高的3D打印机，最早由Josef Průša在2012年完成设计，2015年正式推出商用套件版本，目前最新型号同时提供散件套件和原厂组装版本，具备性价比高、易操作的优势。
DAWN vs IIIV — 直观对比
营收规模更大
IIIV
是对方的1.3倍
$39.8M
营收增速更快
IIIV
高出42.9%
-57.6%
净利率更高
IIIV
高出50.5%
-49.6%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $39.8M | $52.7M |
| 净利润 | $-19.7M | $484.0K |
| 毛利率 | — | — |
| 营业利润率 | -60.9% | 3.1% |
| 净利率 | -49.6% | 0.9% |
| 营收同比 | -57.6% | -14.6% |
| 净利润同比 | -153.3% | -76.5% |
| 每股收益（稀释后） | $-0.19 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DAWNIIIV
| Q4 25 | — | $52.7M | ||
| Q3 25 | $39.8M | $46.0M | ||
| Q2 25 | $33.9M | $51.9M | ||
| Q1 25 | $30.8M | $63.1M | ||
| Q4 24 | — | $52.2M | ||
| Q3 24 | $93.8M | $32.0M | ||
| Q2 24 | — | $46.2M | ||
| Q1 24 | $0 | $58.0M |
净利润DAWNIIIV
| Q4 25 | — | $484.0K | ||
| Q3 25 | $-19.7M | $3.1M | ||
| Q2 25 | $-30.3M | $12.9M | ||
| Q1 25 | $-36.0M | $-154.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $37.0M | $117.9M | ||
| Q2 24 | — | $-7.5M | ||
| Q1 24 | $-62.4M | $1.9M |
营业利润率DAWNIIIV
| Q4 25 | — | 3.1% | ||
| Q3 25 | -60.9% | 3.2% | ||
| Q2 25 | -103.1% | -9.3% | ||
| Q1 25 | -133.5% | 8.0% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | 31.6% | 10.6% | ||
| Q2 24 | — | -2.8% | ||
| Q1 24 | — | 3.4% |
净利率DAWNIIIV
| Q4 25 | — | 0.9% | ||
| Q3 25 | -49.6% | 6.7% | ||
| Q2 25 | -89.4% | 24.8% | ||
| Q1 25 | -117.0% | -0.2% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | 39.5% | 368.2% | ||
| Q2 24 | — | -16.3% | ||
| Q1 24 | — | 3.2% |
每股收益（稀释后）DAWNIIIV
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-0.19 | $0.14 | ||
| Q2 25 | $-0.29 | $0.50 | ||
| Q1 25 | $-0.35 | $0.00 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | $0.38 | $4.93 | ||
| Q2 24 | — | $-0.32 | ||
| Q1 24 | $-0.72 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $451.6M | $37.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.9M | $358.5M |
| 总资产 | $513.8M | $595.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DAWNIIIV
| Q4 25 | — | $37.5M | ||
| Q3 25 | $451.6M | $66.7M | ||
| Q2 25 | $453.1M | $55.5M | ||
| Q1 25 | $473.0M | $7.7M | ||
| Q4 24 | — | $85.6M | ||
| Q3 24 | $558.4M | $86.5M | ||
| Q2 24 | — | $9.7M | ||
| Q1 24 | $317.9M | $3.1M |
总债务DAWNIIIV
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $26.2M | ||
| Q3 24 | — | $26.2M | ||
| Q2 24 | — | $374.1M | ||
| Q1 24 | — | $369.6M |
股东权益DAWNIIIV
| Q4 25 | — | $358.5M | ||
| Q3 25 | $450.9M | $389.6M | ||
| Q2 25 | $460.8M | $383.3M | ||
| Q1 25 | $479.5M | $385.2M | ||
| Q4 24 | — | $375.0M | ||
| Q3 24 | $555.5M | $379.7M | ||
| Q2 24 | — | $249.7M | ||
| Q1 24 | $296.8M | $249.3M |
总资产DAWNIIIV
| Q4 25 | — | $595.9M | ||
| Q3 25 | $513.8M | $638.4M | ||
| Q2 25 | $519.0M | $623.3M | ||
| Q1 25 | $534.4M | $646.4M | ||
| Q4 24 | — | $726.2M | ||
| Q3 24 | $600.8M | $730.7M | ||
| Q2 24 | — | $861.7M | ||
| Q1 24 | $326.6M | $625.8M |
负债/权益比DAWNIIIV
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 1.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | $14.1M |
| 自由现金流经营现金流 - 资本支出 | — | $13.8M |
| 自由现金流率自由现金流/营收 | — | 26.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 29.18× |
| 过去12个月自由现金流最近4个季度 | — | $6.5M |
8季度趋势，按日历期对齐
经营现金流DAWNIIIV
| Q4 25 | — | $14.1M | ||
| Q3 25 | $-5.8M | $14.0M | ||
| Q2 25 | $-24.8M | $7.4M | ||
| Q1 25 | $-59.0M | $-27.1M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | $50.8M | $15.1M | ||
| Q2 24 | — | $8.1M | ||
| Q1 24 | $-49.7M | $10.7M |
自由现金流DAWNIIIV
| Q4 25 | — | $13.8M | ||
| Q3 25 | — | $13.5M | ||
| Q2 25 | $-24.8M | $6.8M | ||
| Q1 25 | $-59.3M | $-27.6M | ||
| Q4 24 | — | $11.0M | ||
| Q3 24 | $50.0M | $14.6M | ||
| Q2 24 | — | $7.2M | ||
| Q1 24 | — | $9.9M |
自由现金流率DAWNIIIV
| Q4 25 | — | 26.2% | ||
| Q3 25 | — | 29.5% | ||
| Q2 25 | -73.2% | 13.1% | ||
| Q1 25 | -192.8% | -43.8% | ||
| Q4 24 | — | 21.1% | ||
| Q3 24 | 53.4% | 45.6% | ||
| Q2 24 | — | 15.6% | ||
| Q1 24 | — | 17.1% |
资本支出强度DAWNIIIV
| Q4 25 | — | 0.6% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 1.0% | 0.8% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | 0.8% | 1.7% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 1.4% |
现金转化率DAWNIIIV
| Q4 25 | — | 29.18× | ||
| Q3 25 | — | 4.52× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.59× | ||
| Q3 24 | 1.37× | 0.13× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
IIIV
| License And Service | $35.7M | 68% |
| Proprietary Payments Revenue | $14.5M | 27% |
| Other Revenue | $2.5M | 5% |
